Early detection of Alzheimer's disease using PiB and FDG PET.

Abstract

Use of biomarkers in the detection of early and preclinical Alzheimer's disease (AD) has become of central importance following publication of the NIA-Alzheimer's Association revised criteria for the diagnosis of AD, mild cognitive impairment (MCI) and preclinical AD. The use of in vivo amyloid imaging agents, such a Pittsburgh Compound-B and markers of neurodegeneration, such as fluoro-2-deoxy-D-glucose (FDG) is able to detect early AD pathological processes and subsequent neurodegeneration. Imaging with PiB and FDG thus has many potential clinical benefits: early or perhaps preclinical detection of disease and accurately distinguishing AD from dementias of other etiologies in patients presenting with mild or atypical symptoms or confounding comorbidities in which the diagnostic distinction is difficult to make clinically. From a research perspective, this allows us to study relationships between amyloid pathology and changes in cognition, brain structure, and function across the continuum from normal aging to MCI to AD. The present review focuses on use of PiB and FDG-PET and their relationship to one another.

• Authors: Ann D Cohen, William E Klunk
• Journal: Neurobiology of disease (Neurobiol Dis) Vol. 72 Pt A Pg. 117-22 (Dec 2014) ISSN: 1095-953X [Electronic] United States
• PMID: 24825318 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2014 Elsevier Inc. All rights reserved.

Chemical References

• 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
• Amyloid beta-Peptides
• Aniline Compounds
• Biomarkers
• Thiazoles
• Fluorodeoxyglucose F18
• Glucose

Topics

• Alzheimer Disease (diagnostic imaging, pathology)
• Amyloid beta-Peptides (metabolism)
• Aniline Compounds
• Biomarkers (metabolism)
• Brain (diagnostic imaging, metabolism)
• Cognition (physiology)
• Cognitive Dysfunction (diagnostic imaging, pathology)
• Fluorodeoxyglucose F18
• Glucose (metabolism)
• Humans
• Positron-Emission Tomography
• Thiazoles